

## Soliris (eculizumab) and Biosimilars

- Bkemy (eculizumab-aeab)
- Epysqli (eculizumab-aagh)
- Soliris (eculizumab)

### Disclaimer

*Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.*

*Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.*

Soliris (eculizumab) and Biosimilars	1
Summary	2
Definitions	3
Medical Necessity Criteria for Clinical Review	5
General Medical Necessity Criteria	5
Medical Necessity Criteria for Initial Clinical Review	5
Initial Indication-Specific Criteria	5
Atypical hemolytic uremic syndrome (aHUS)	5
Generalized myasthenia gravis (gMG)	6
Neuromyelitis Optica Spectrum Disorder (NMOSD)	6
Paroxysmal Nocturnal Hemoglobinuria (PNH)	7
Medical Necessity Criteria for Subsequent Clinical Review	8
Subsequent General Medical Necessity Criteria	8
Medical Necessity Criteria for Subsequent Clinical Review	8
Subsequent Indication-Specific Criteria	8
Atypical Hemolytic Uremic Syndrome (aHUS)	8
Generalized Myasthenia Gravis	9

Neuromyelitis Optica Spectrum Disorder	9
Paroxysmal Nocturnal Hemoglobinuria (PNH)	9
Experimental or Investigational / Not Medically Necessary	10
Applicable Billing Codes	10
References	12
Appendix A	14
Clinical Guideline Revision / History Information	16

## Summary

Soliris (eculizumab) is a recombinant humanized monoclonal antibody that specifically binds to the complement protein C5, inhibiting its cleavage into C5a and C5b and preventing the generation of the terminal complement complex C5b-9. By inhibiting terminal complement activity, Soliris (eculizumab) reduces intravascular hemolysis in PNH, complement-mediated thrombotic microangiopathy in aHUS, anti-AChR antibody-mediated neuromuscular damage in gMG, and complement-mediated injury to the central nervous system in NMOSD. Soliris (eculizumab) is FDA-approved for the following conditions:

1. Treatment of paroxysmal nocturnal hemoglobinuria (PNH)
2. Atypical hemolytic uremic syndrome (aHUS)  
*Note: Soliris (eculizumab) and biosimilars is not indicated for the treatment of Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS)*
3. Anti-acetylcholine receptor antibody positive generalized myasthenia gravis (gMG) in those 6 years of age and older
4. Anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (NMOSD) in adults.

Soliris (eculizumab) has a boxed warning for the risk of serious meningococcal infections. It is recommended that one completes or updates their meningococcal vaccination at least 2 weeks prior to the first dose of Soliris (eculizumab), unless the risk of delaying therapy outweighs the risk of developing a serious infection. Even those who develop antibodies following meningococcal vaccination are at risk for invasive disease caused by *Neisseria meningitidis*. All individuals on Soliris (eculizumab) should be monitored closely for early signs and symptoms of meningococcal infections.

Soliris (eculizumab) biosimilars are available: Bkembv (eculizumab-aeab), and Epysqli (eculizumab-aagh). They are approved for the following indications:

1. Treatment of paroxysmal nocturnal hemoglobinuria (PNH)
2. Atypical hemolytic uremic syndrome (aHUS)  
*Note: Bkembv (eculizumab-aeab) and Epysqli (eculizumab-aagh) are not indicated for the treatment of Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS)*
3. Anti-acetylcholine receptor antibody positive generalized myasthenia gravis (gMG) in adults.

## Definitions

"Acute Kidney Injury" refers to an acute condition in which there is a sudden decline in kidney function.

"Anti-acetylcholine receptor (anti-AChR) antibodies" are autoantibodies directed against the nicotinic acetylcholine receptor found at the neuromuscular junction.

"Atypical hemolytic uremic syndrome (aHUS)" is an ultra-rare, life-threatening genetic disorder caused by chronic, uncontrolled activation of the alternative complement pathway, resulting in complement-mediated thrombotic microangiopathy (TMA).

"Cholinesterase inhibitors" refer to a class of drugs that prevent the breakdown of acetylcholine, a neurotransmitter which plays a major role in memory and muscle movement and contraction.

"Documentation" refers to written information, including but not limited to:

- Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses; or
- Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives.

"Expanded Disability Status Scale (EDSS)" is a clinical tool used in patients with multiple sclerosis (MS), to assess level of disability. The scale ranges from 0 to 10, with higher values associated with greater disability. See [Appendix, table 3](#).

"Flow cytometry" is a tool used to rapidly assess the characteristics of a single cell using lasers in a buffered salt solution.

"Generalized myasthenia gravis (gMG)" is an autoimmune neuromuscular disease caused by antibodies that attack components of the neuromuscular junction (NMJ), impairing transmission between nerve and muscle, resulting in muscle weakness and fatigue.

"Immunomodulatory biologics" are large molecule drugs used to change one's immune response.

"Immunosuppressives," or immunosuppressive therapies, are any agent aimed at reducing the body's immune response, which may be used to treat conditions characterized by overactive immune systems, or to avoid rejection of bone marrow or organ transplant.

"Myasthenia Gravis Activities of Daily Living (MG-ADL) score" is a validated, 8-item patient-reported scale that assesses the impact of myasthenia gravis on daily functions.

"Myasthenia Gravis Foundation of America (MGFA) Clinical Classification" is a commonly used classification system that defines myasthenia gravis severity based on the degree and distribution of muscle weakness.

"Neuromyelitis optica spectrum disorder (NMOSD)" is a chronic inflammatory disorder of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting the optic nerves and spinal cord. The majority of patients have autoantibodies to aquaporin-4 (AQP4).

"No evidence of" indicates that the reviewer has not identified any records of the specified item or condition within the submitted materials or claims history. In the absence of such evidence, the member is considered eligible. If any evidence of the item or condition is present upon review of the request, the member does not qualify.

"Paroxysmal nocturnal hemoglobinuria (PNH)" refers to a rare, acquired, life-threatening disease of the blood characterized by complement-mediated hemolysis, thrombosis, and bone marrow failure.

"Quantitative Myasthenia Gravis (QMG) score" is a 13-item physician-administered scale that measures the severity of myasthenia gravis based on muscle weakness assessment.

"Relapse" refers to a deterioration or recurrence of a disease state after a temporary improvement.

"[s]" indicates state mandates may apply.

"Thrombocytopenia" is a condition characterized by very low platelets in the blood.

"Thrombotic microangiopathy" refers to a group of rare disorders which is characterized by blood clots in small blood vessels, low platelet count, and the destruction of red blood cells.

"Thrombotic thrombocytopenic purpura" is a rare condition characterized by small blood clots in small blood vessels throughout the body, limiting or blocking the flow of blood to important areas of the body such as the heart, kidneys or brain.

## Medical Necessity Criteria for Clinical Review

### General Medical Necessity Criteria

The Plan considers Soliris (eculizumab), Bkemy (eculizumab-aeab), or Epysqli (eculizumab-aagh) medically necessary when ALL the following criteria are met:

1. The drug is prescribed by, or in consultation with, a physician who specializes in the treatment of the specific condition:

- a. Atypical hemolytic uremic syndrome (aHUS) - hematologist or nephrologist; *or*
  - b. Generalized myasthenia gravis (gMG) - neurologist or neuromuscular disease specialist;  
*or*
  - c. Paroxysmal Nocturnal Hemoglobinuria (PNH) - hematologist; *or*
  - d. Neuromyelitis Optica Spectrum Disorder (NMOSD) - neurologist or neuro-ophthalmologist; *AND*
2. The drug is being prescribed at a dose and frequency that is within FDA approved labeling OR is supported by compendia or evidence-based published dosing guidelines for the requested indication; *AND*
  3. The member meets the applicable [Medical Necessity Criteria for Initial Clinical Review](#) or [Subsequent Clinical Review](#) listed below.

### Medical Necessity Criteria for Initial Clinical Review

#### Initial Indication-Specific Criteria

#### Atypical hemolytic uremic syndrome (aHUS)

The Plan considers Soliris (eculizumab), Bkemy (eculizumab-aeab), or Epysqli (eculizumab-aagh) medically necessary when ALL the following criteria are met:

4. The member is at least 1 month of age; *AND*
5. The member has a diagnosis of aHUS confirmed by ALL of the following :
  - a. ADAMTS13 activity level above 5%; *and*
  - b. No evidence of Shiga toxin E. coli-related HUS (STEC-HUS)( e.g., STEC-test negative in members with a history of bloody diarrhea in the preceding 2-weeks); *AND*
6. The member has documented presence of thrombotic microangiopathy, as evidenced by ALL of the following:
  - a. Microangiopathic hemolytic anemia (e.g., anemia, increased LDH, decreased haptoglobin, increased indirect bilirubin, increased AST, elevated reticulocyte count, presence of schistocytes, helmet cells, and burr cells on peripheral blood smear); *and*
  - b. Thrombocytopenia, defined as a platelet count below 150,000/microliter; *and*
  - c. Acute kidney injury (e.g., elevated serum creatinine, oliguria, presence of hematuria, proteinuria, pyuria, casts on urinalysis) or member requires dialysis; *AND*
7. The requested medication will not be used in combination with another complement inhibitor (e.g., Ultomiris [ravulizumab-cwvz]) for the treatment of aHUS.

If the above prior authorization criteria are met, Soliris (eculizumab) and biosimilars will be authorized for up to 6-months.<sup>[5]</sup>

### Generalized myasthenia gravis (gMG)

The Plan considers Soliris (eculizumab), Bkemy (eculizumab-aeeb), or Epysqli (eculizumab-aagh) medically necessary when ALL the following criteria are met:

4. The member is 6 years of age or older; *AND*
5. The member has a confirmed diagnosis of generalized myasthenia gravis (gMG) *AND* documentation of ALL of the following:
  - a. Positive serologic test for anti-acetylcholine receptor (anti-AChR) antibodies; *and*
  - b. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IV (see [Appendix A, Table 3](#)); *and*
  - c. Baseline Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score of at least ( $\geq$ ) 6; *AND*
6. The member meets ONE (1) of the following:
  - a. The member is 17 years of age or younger *AND* has life-threatening or rapidly-progressive gMG, where earlier use of complement inhibition is warranted; *or*
  - b. The member is unable to use, limited by toxicity, or has adequately tried and failed or experienced insufficient response to at least TWO (2) standard therapies for gMG, such as:<sup>1a</sup>
    - i. Cholinesterase inhibitors (e.g., pyridostigmine); *and/or*
    - ii. Corticosteroids (e.g., prednisone) or inability to taper steroids below a reasonably acceptable level without return of symptoms; *and/or*
    - iii. Immunosuppressive therapies (e.g., azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide, tacrolimus); *AND*
7. The requested medication will not be used in combination with another complement inhibitor (e.g., Ultomiris [ravulizumab-cwvz], Zilbrysq [zilucoplan]) or neonatal Fc receptor blocker (e.g., Vyvgart [efgartigimod alfa], Vyvgart Hytrulo [efgartigimod alfa and hyaluronidase-qvfc], Rystiggo [rozanolixizumab-noli])

If the above prior authorization criteria are met, Soliris (eculizumab) will be authorized for up to 6-months.<sup>1a</sup>

### Neuromyelitis Optica Spectrum Disorder (NMOSD)

The Plan considers Soliris (eculizumab) medically necessary when ALL the following criteria are met:

4. The member is 18 years of age or older; *AND*
5. The member has confirmed diagnosis of NMOSD, as evidenced by a positive serologic test for anti-aquaporin-4 (AQP4) antibodies; *AND*
6. The member must have experienced at least ONE (1) of the following:
  - a. 2 or more relapses in the 12 months prior; *or*
  - b. 3 or more relapses in the 24 months prior, with at least 1 relapse occurring within the last 12 months; *AND*

7. The member has an Expanded Disability Status Scale (EDSS) score of  $\leq 7$  (i.e., presence of at least limited ambulation with aid) (see [Appendix A, Table 4](#)); *AND*
8. Soliris (eculizumab) will NOT be initiated during a NMOSD relapse episode; *AND*
9. The member will not receive the requested medication concomitantly with other biologics for the treatment of NMOSD (e.g., Uplizna [inebilizumab], Enspryng [satralizumab], Ultomiris [ravulizumab]).

If the above prior authorization criteria are met, Soliris (eculizumab) will be authorized for up to 6-months.<sup>[5]</sup>

#### Paroxysmal Nocturnal Hemoglobinuria (PNH)

The Plan considers Soliris (eculizumab), Bkemyv (eculizumab-aeab), or Epysqli (eculizumab-aagh) medically necessary when ALL the following criteria are met:

4. The member is at least 1 month of age; *AND*
5. There is a diagnosis of PNH confirmed by flow cytometry demonstrating a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs) with ONE (1) of the following:
  - a. At least 5% PNH cells (i.e., cells lacking GPI-AP expression); *or*
  - b. At least 51% of GPI-deficient poly-morphonuclear cells (e.g., neutrophils deficient in GPI-APs); *AND*
6. The member has documentation of ONE (1) of the following:
  - a. Hemoglobin  $\leq 9$  g/dL with symptomatic anemia, or hemoglobin  $\leq 7$  g/dL; *and/or*
  - b. Absolute reticulocyte count  $\geq 2$  times the upper limit of normal; *and/or*
  - c. Thrombosis; *and/or*
  - d. Transfusion dependence ( $\geq 2$  transfusions in the last 12 months); *and/or*
  - e. Lactate dehydrogenase  $>1.5$  times the upper limit of normal; *and/or*
  - f. Renal dysfunction; *and/or*
  - g. Pulmonary hypertension; *and/or*
  - h. Dysphagia; *AND*
7. The requested medication will not be used in combination with another complement inhibitor (e.g., Empaveli [pegcetacoplan], Fabhalta [iptacoplan], Piasyq [crovalimab], Ultomiris [ravulizumab]) for the treatment of PNH (concomitant use with Voydeya [danicoplan] is allowed).

If the above prior authorization criteria are met, Soliris (eculizumab) will be authorized for up to 6-months.<sup>[5]</sup>

#### *Continued Care*

#### **Medical Necessity Criteria for Subsequent Clinical Review**

##### Subsequent General Medical Necessity Criteria

The Plan considers Soliris (eculizumab), Bkemyv (eculizumab-aeab), or Epysqli (eculizumab-aagh) medically necessary when ALL the following criteria are met:

1. Prescribed by, or in consultation with, a physician who specializes in the treatment of the specific condition:
  - a. Atypical hemolytic uremic syndrome (aHUS) - hematologist or nephrologist; *or*
  - b. Generalized myasthenia gravis (gMG) - neurologist or neuromuscular disease specialist; *or*
  - c. Neuromyelitis Optica Spectrum Disorder (NMOSD) - neurologist or neuro-ophthalmologist; *or*
  - d. Paroxysmal Nocturnal Hemoglobinuria (PNH) - hematologist; *AND*
2. There is no evidence of unacceptable toxicity or adverse reaction to therapy, such as:
  - a. Serious infections (e.g. serious respiratory or urinary tract infections); *and/or*
  - b. Severe hypersensitivity reactions; *and/or*
  - c. Severe immunosuppression; *and/or*
  - d. Other intolerable side effects or reactions; *AND*
3. Soliris (eculizumab) is being prescribed at a dose and frequency that is within FDA approved labeling OR is supported by compendia or evidence-based published dosing guidelines for the requested indication; *AND*
4. Ongoing therapy is required to maintain disease stability and control; *AND*
5. The member meets the applicable [Medical Necessity Criteria for Subsequent Clinical Review](#) listed below.

### Medical Necessity Criteria for Subsequent Clinical Review

#### Subsequent Indication-Specific Criteria

#### Atypical Hemolytic Uremic Syndrome (aHUS)

The Plan considers Soliris (eculizumab), Bkemy (eculizumab-aeab), or Epysqli (eculizumab-aagh) medically necessary when BOTH the following criteria are met:

6. The member has experienced ONE (1) positive clinical response to therapy defined as ONE (1) of the following:
  - a. Improvement or normalization of lactate dehydrogenase (LDH) levels and/or haptoglobin; *or*
  - b. Improvement or normalization of platelet counts; *or*
  - c. Improvement in serum creatinine from baseline and/or stabilization of renal function; *or*
  - d. Reduction or absence of schistocytes or fragmented red blood cells on peripheral blood smear; *or*
  - e. Improvement in hemoglobin levels from baseline; *AND*
7. The requested medication will not be used in combination with another complement inhibitor (e.g., Ultomiris [ravulizumab-cwvz]) for the treatment of aHUS.

### Generalized Myasthenia Gravis

The Plan considers Soliris (eculizumab), Bkemy (eculizumab-aeeb), and Epysqli (eculizumab-aagh) medically necessary when BOTH the following criteria are met:

6. The member has experienced ONE (1) positive clinical response to therapy defined as ONE of the following:
  - a. Improvement in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score; *or*
  - b. MG Manual Muscle Test (MMT); *or*
  - c. MG Composite; *or*
  - d. Quantitative Myasthenia Gravis (QMG) score from baseline; *or*
  - e. Achievement of minimal symptom expression or pharmacological remission; *or*
  - f. Lack of relapses or reduced frequency/severity of relapses compared to baseline; **AND**
7. The requested medication will not be used in combination with another complement inhibitor (e.g., Ultomiris [ravulizumab-cwvz], Zilbrysq [zilucoplan]) or neonatal Fc receptor blocker (e.g., Vyvgart [efgartigimod alfa], Vyvgart Hytrulo [efgartigimod alfa and hyaluronidase-qvfc], Rystiggo [rozanolixizumab-noli]).

### Neuromyelitis Optica Spectrum Disorder

The Plan considers Soliris (eculizumab) medically necessary when BOTH the following criteria are met:

6. The member has experienced ONE (1) positive clinical response to therapy defined as ONE of the following:
  - a. Reduction in the frequency and/or severity of relapses; *or*
  - b. Stabilization or improvement in disability scores; *or*
  - c. Absence of new lesions on MRI; *or*
  - d. Improvement or stabilization of neurologic symptoms; *or*
  - e. Reduced hospitalizations; *or*
  - f. Reduction/discontinuation in plasma exchange treatment; **AND**
7. The member will not receive the requested medication concomitantly with other biologics for the treatment of NMOSD (e.g., Uplizna [inebilizumab], Enspryng [satralizumab], Ultomiris [ravulizumab]).

### Paroxysmal Nocturnal Hemoglobinuria (PNH)

The Plan considers Soliris (eculizumab), Bkemy (eculizumab-aeeb), or Epysqli (eculizumab-aagh) medically necessary when BOTH the following criteria are met:

6. The member has experienced ONE (1) positive clinical response to therapy defined as ONE of the following:
  - a. Improvement or stabilization of hemoglobin levels; *or*
  - b. Decreased transfusion requirements; *or*
  - c. Reduced hemolysis; *or*
  - d. Improvement in PNH symptoms; *or*
  - e. Improvement or normalization of lactate dehydrogenase (LDH) levels; **AND**

7. The requested medication will not be used in combination with another complement inhibitor (e.g., Empaveli [pegcetacoplan], Fabhalta [iptacopan], Piasky [crovalimab], Ultomiris [ravulizumab]) for the treatment of PNH (concomitant use with Voydeya [danicopan] is allowed).

If the above reauthorization criteria are met, the requested product will be authorized for up to 12 months.<sup>[s]</sup>

#### Experimental or Investigational / Not Medically Necessary<sup>[s]</sup>

Soliris (eculizumab) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. Non-covered indications include, but are not limited to, the following:

- Antibody-mediated transplant rejection (excluding cardiac and renal transplants). High quality studies are limited to support the safety and efficacy of Soliris (eculizumab) and biosimilars for the management of antibody-mediated transplant rejection outside of cardiac and renal transplants.
- Post-transplant recurrence of atypical hemolytic uremic syndrome (aHUS). There are no high quality studies to support the safety and efficacy of Soliris (eculizumab) and biosimilars for the management of post-transplant recurrent of aHUS.
- Shiga toxin Escherichia coli-related hemolytic uremic syndrome (STEC-HUS). The FDA labeling explicitly states that Soliris (eculizumab) is not indicated for STEC\_HUS. A phase 3 randomized controlled trial of 100 pediatric participants did not find improvement in renal outcomes in those exposed for Soliris (eculizumab) versus placebo.
- Thrombotic thrombocytopenic purpura (TTP). Clinical studies supporting the use of Soliris (eculizumab) and biosimilars have been limited to the management of aHUS, and ruling out the possibility of TTP.
- Other complement-mediated diseases or conditions not listed above as medically necessary. There is limited evidence to support the use of Soliris (eculizumab) in the management of other complement-mediated diseases or conditions outside of PNH, NMOSD, aHUG and gMG
- Use in patients who have unresolved serious *Neisseria meningitidis* infection or are not adequately vaccinated against *Neisseria meningitidis*. Soliris (eculizumab) and its biosimilars have a boxed warning related to the risk of *N. meningitidis* risk. See the Summary section for complete information.

#### Applicable Billing Codes

Table 1
CPT/HCPCS codes for atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD), and paroxysmal nocturnal hemoglobinuria (PNH) considered medically necessary if criteria are met:

Table 1	
<i>Code</i>	<i>Description</i>
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
J1299	Injection, eculizumab, 2 mg
Q5151	Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg
Q5152	Injection, eculizumab-aeab (bkemv), biosimilar, 2 mg

Table 2	
ICD-10 codes considered medically necessary for atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD), and paroxysmal nocturnal hemoglobinuria (PNH) with Table 1 (CPT/HCPCS) codes if criteria are met:	
<i>Code</i>	<i>Description</i>
D59.3	Hemolytic-uremic syndrome
D59.30	Hemolytic-uremic syndrome, unspecified
D59.31	Infection-associated hemolytic-uremic syndrome
D59.32	Hereditary hemolytic-uremic syndrome
D59.39	Other hemolytic-uremic syndrome
D59.5	Paroxysmal nocturnal hemoglobinuria
G36.0	Neuromyelitis optica
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation
G70.2	Congenital and developmental myasthenia

## References

1. Cancado RD, Araujo AS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. *Hematol Transfus Cell Ther.* 2020 Jul 6; 43(3):341-348. doi:10.1016/j.htct.2020.05.006.
2. Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. *Blood.* 2015 May 21;125(21):3253-62. doi: 10.1182/blood-2014-09-600411. Epub 2015 Apr 1. PMID: 25833956; PMCID: PMC4449039.
3. Garnier A, Brochard K, Kwon T, et al. Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial. *J Am Soc Nephrol.* 2023 Sep 1;34(9):1561-1573. doi: 10.1681/ASN.000000000000182. Epub 2023 Jun 12.
4. Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. *Kidney Int.* 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026. Epub 2016 Jan 28.
5. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. *N Engl J Med.* 2009; 360:544-6. [PubMed 19179329]
6. Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. *N Engl J Med.* 2006; 355:1233-43. [PubMed 16990386].
7. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol.* 2017 Dec; 16(12):976-986. doi:10.1016/S147404422(17)30369-1. Epub 2017 Oct 20.
8. Jacob S, Farrugia ME, Hewamadduma C, et al. Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update). *Pract Neurol.* 2025 Sep 12;25(5):422-437. doi: 10.1136/pn-2025-004655.
9. Java A. Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy. *Hematology Am Soc Hematol Educ Program.* 2024 Dec 6;2024(1):200-205. doi: 10.1182/hematology.2024000543.
10. Kittleson MM, Patel N, Chang DH, Kransdorf EP, Kobashigawa JA, Patel JK. Eculizumab for antibody-mediated rejection in heart transplantation: a case-control study. *Clin Transplant.* 2021;35(12):e14454. doi:10.1111/ctr.14454[PubMed 34402096]
11. Kulasekararaj A, Griffin M, Piatek C, et al. Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH. *Blood.* 2025 Feb 20;145(8):811-822. doi: 10.1182/blood.2024026299.
12. Kulkarni S, Kirkiles-Smith NC, Deng YH, et al. Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial. *Am J Transplant.* 2017;17(3):682-691. doi:10.1111/ajt.14001[PubMed 27501352]
13. Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in severe Shiga-toxin-associated HUS. *N Engl J Med.* 2011; 364:2561-3. [PubMed 21612462]
14. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med.* 2013; 368:2169-81. [PubMed 23738544].
15. Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Füreder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L, Aguzzi R, Pradhan R, Schrezenmeier H, Hill A. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. *Blood.* 2019 Feb 7;133(6):530-539. doi: 10.1182/blood-2018-09-876136. Epub 2018 Dec 3. PMID: 30510080; PMCID: PMC6367644.
16. Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. *Kidney Int.* 2015 May;87(5):1061-73. doi: 10.1038/ki.2014.423. Epub 2015 Feb 4. PMID: 25651368; PMCID: PMC4424817.

17. Marks WH, Mamode N, Montgomery RA, et al; C10-001 Study Group. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. *Am J Transplant*. 2019;19(10):2876-2888. doi:10.1111/ajt.15364[PubMed 30887675]
18. McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. *MMWR Morb Mortal Wkly Rep*. 2017 Jul 14;66(27):734-737. doi: 10.15585/mmwr.mm6627e1.
19. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. *Neurology*. 2021;96(3):114-122. doi:10.1212/WNL.00000000000011124[PubMed 33144515]
20. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. *N Engl J Med*. 2009; 361:1676-87. [PubMed 19846853]
21. Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. *N Engl J Med*. 2009; 360:542-4. [PubMed 19179328]
22. O'Connell K, Ramdas S, Palace J. Management of Juvenile Myasthenia Gravis. *Front Neurol*. 2020 Jul 24;11:743. doi: 10.3389/fneur.2020.00743.
23. Patel JK, Coutance G, Loupy A, et al. Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. *Am J Transplant*. 2021;21(7):2479-2488. doi:10.1111/ajt.16420[PubMed 33251691].
24. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. *N Engl J Med*. 2019 Aug 15;381(7):614-625. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3. PMID: 31050279.
25. Pittock SJ, Fujihara K, Palace J, et al. Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. *Mult Scler*. 2022 Mar;28(3):480-486. doi:10.1177/13524585211038291. Epub 2021 Sep 9.
26. Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. *Cochrane Database Syst Rev*. 2021 Mar 23;3(3):CD012862. doi: 10.1002/14651858.CD012862.pub2. PMID: 33783815; PMCID: PMC8078160.
27. Rees L. Atypical HUS: time to take stock of current guidelines and outcome measures?. *Pediatr Nephrol*. 2013; 28:675-7. [PubMed 23389238].
28. Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. *Front Immunol*. 2019 Jun 14;10:1157. doi: 10.3389/fimmu.2019.01157. PMID: 31258525; PMCID: PMC6587878.
29. Röth A, Fu R, He G, et al. Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies. *Eur J Haematol*. 2025 Feb;114(2):373-382. doi: 10.1111/ejh.14339. Epub 2024 Nov 13.
30. Schinstock CA, Bentall AJ, Smith BH, et al. Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies. *Am J Transplant*. 2019;19(6):1671-1683. doi:10.1111/ajt.15175[PubMed 30412654]
31. Schmidtko J, Peine S, El-Housseini Y et al. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. *Am J Kidney Dis*. 2013; 61:289-99. [PubMed 23141475]
32. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. *Br J Haematol*. 2012 Aug;158(3):323-35. doi: 10.1111/j.1365-2141.2012.09167.x. Epub 2012 May 25.
33. Socié G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. *Br J Haematol*. 2019;185(2):297-310. doi:10.1111/bjh.15790[PubMed 30768680]

34. Soliris (eculizumab) [prescribing information]. Boston, MA: Alexion Pharmaceuticals Inc; September 2024.
35. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. *Am J Transplant.* 2011;11(11):2405-2413. doi:10.1111/j.1600-6143.2011.03757.x[PubMed 21942930]
36. Tan EK, Bentall A, Dean PG, Shaheen MF, Stegall MD, Schinstock CA. Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases. *Transplantation.* 2019;103(11):2397-2404. doi:10.1097/TP.0000000000002639[PubMed 30801549]
37. Tschumi S, Gugger M, Bucher BS et al. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. *Pediatr Nephrol.* 2011; 26:2085-8. [PubMed 21877169]
38. Ultomiris (ravulizumab-cwvz) [prescribing information]. Boston, MA: Alexion Pharmaceuticals Inc.; September 2024.
39. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. *J Heart Lung Transplant.* 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015[PubMed 37080658]
40. Vilalta R, Lara E, Madrid A et al. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. *Pediatr Nephrol.* 2012; 27:2323-6. [Free Fulltext PMC][PubMed 22890512]
41. Vivarelli M, Barratt J, Beck LH Jr, et al. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int.* 2024 Sep;106(3):369-391. doi: 10.1016/j.kint.2024.05.015. Epub 2024 Jun 4.
42. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology.* 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.
43. Wingerchuk DM, Fujihara K, Palace J, et al. Long-term safety and efficacy of eculizumab in Aquaporin-4 IgG-positive NMOSD. *Ann Neurol.* 2021 Jun;89(6):1088-1098. doi:10.1002/ana.26049. Epub 2021 Feb 27.
44. Yerly P, Rotman S, Regamey J, et al. Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation. *Xenotransplantation.* 2022;29(1):e12726. doi:10.1111/xen.12726[PubMed 35001433]
45. Yamout B, Gouider R, Al-Roughani R, et al. Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines. *CNS Drugs.* 2026 Jan 27. doi: 10.1007/s40263-025-01260-x. Epub ahead of print.
46. Young NS, Antonioli E, Rotoli B et al. Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: SHEPHERD phase III clinical study results. Paper presented at American Society of Hematology Annual Meeting. Orlando, FL: 2006 Dec 9.

## Appendix A

Table 3: Summary of Myasthenia Gravis Foundation of America (MGFA) Disease Clinical Classification

<i>Class</i>	<i>Description</i>
I	Ocular muscle weakness; All other muscles - normal strength
II	Mild generalized weakness
Ila	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible

IIb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
III	Moderate generalized weakness
IIIa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IIIb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
IV	Severe generalized weakness
IVa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IVb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
V	Intubation, with or without ventilation; Not for routine postoperative care

**NOTE:** The preceding table summarizes key aspects of the Myasthenia Gravis Foundation of America (MGFA) Disease Classifications. This is provided only for quick reference. For the exact definitions and details on the MGFA Disease Classifications, please refer to the original MGFA Classification document available at <https://myasthenia.org/Portals/0/MGFA%20Classification.pdf>.

Table 4: Expanded Disability Status Scale (EDSS)

Score	Description
0	Normal neurological examination, no disability in any functional system
1.0	No disability, minimal signs in one functional system
1.5	No disability, minimal signs in more than one functional system
2.0	Minimal disability in one functional system
2.5	Mild disability in one functional system or minimal disability in two functional systems
3.0	Moderate disability in one functional system, or mild disability in three or four functional systems. No walking impairment
3.5	Moderate disability in one functional system and more than minimal disability in several others. No walking impairment
4.0	Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk without aid or rest for 500m
4.5	Significant disability but up and about much of the day. Able to work a full day. May otherwise have some limitation of full activity or require minimal assistance. Able to walk without aid or rest for 300m

5.0	Disability severe enough to impair full daily activities and ability to work a full day without special provisions. Able to walk without aid or rest for 200m
5.5	Disability severe enough to prevent full daily activities. Able to walk without aid or rest for 100m
6.0	Requires a walking aid – cane, crutch, etc. – to walk about 100m with or without resting
6.5	Requires two walking aids – pair of canes, crutches, etc. – to walk about 20m without resting
7.0	Unable to walk beyond approximately 5m even with aid. Essentially restricted to a wheelchair; though wheels a standard wheelchair and able to get in and out alone. Up and about in wheelchair some 12 hours a day
7.5	Unable to take more than a few steps. Restricted to a wheelchair and may need help getting in and out. Can wheel but cannot carry on in a standard wheelchair for a full day and may require a motorised wheelchair
8.0	Essentially restricted to a bed or chair or being pushed in wheelchair. May be out of bed much of the day. Retain many self-care functions. Generally has effective use of arms
8.5	Essentially restricted to a bed for much of the day. Has some effective use of arms, retains some self-care functions
9.0	Confined to bed. Can still communicate and eat
9.5	Confined to bed and totally dependent. Unable to communicate effectively or eat/swallow
10.0	Death due to MS

**NOTE:** The preceding table summarizes key aspects of the Expanded Disability Status Scale (EDSS). This is provided only for quick reference. For the exact definitions and details on the EDSS, please refer to the original EDSS document available at <https://mstrust.org.uk/a-z/expanded-disability-status-scale-edss>

Clinical Guideline Revision / History Information

Original Date: 3/21/2024  
 Reviewed/Revised: 7/1/2025, 02/02/2026, 07/01/2026